Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR5 | P51681 | 5/20 | 0.62 |
| ▸ | RORC | P51449 | 1/20 | 0.61 |
| ▸ | HTR2C | P28335 | 7/20 | 0.51 |
| ▸ | HTR2B | P41595 | 6/20 | 0.51 |
| ▸ | HTR2A | P28223 | 4/20 | 0.51 |
| ▸ | MAOB | P27338 | 2/20 | 0.51 |
| ▸ | KDM1A | O60341 | 1/20 | 0.49 |
| ▸ | GBA1 | P04062 | 1/20 | 0.48 |
| ▸ | FUCA1 | P04066 | 2/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7887325 | 1.00 | CCR5 (0.62) | CCR5RORCHTR2CHTR2BHTR2A | |
| SCHEMBL1202491 | 1.00 | CCR5 (0.62) | CCR5RORCHTR2CHTR2BHTR2A | |
| SCHEMBL1935588 | 0.91 | RORC (0.59) | CCR5RORCHTR2CHTR2BHTR2A | |
| SCHEMBL1203067 | 0.91 | RORC (0.59) | CCR5RORCHTR2CHTR2BHTR2A | |
| SCHEMBL1975960 | 0.91 | RORC (0.59) | CCR5RORCHTR2CHTR2BHTR2A | |
| SCHEMBL1202337 | 0.90 | RORC (0.58) | CCR5RORCHTR2CHTR2BHTR2A | |
| SCHEMBL2226943 | 0.90 | RORC (0.58) | CCR5RORCHTR2CHTR2BHTR2A | |
| SCHEMBL1976472 | 0.90 | RORC (0.58) | CCR5RORCHTR2CHTR2BHTR2A | |
| SCHEMBL1938171 | 0.87 | CCR5 (0.67) | CCR5RORCHTR2CHTR2BHTR2A | |
| SCHEMBL4640399 | 0.86 | FUCA1 (0.56) | CCR5RORCGBA1FUCA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2364295-B1 | 3-(BENZYLAMINO)-PYRROLIDINE DERIVATIVES AND THEIR USE AS NK-3 RECEPTOR ANTAGONISTS | HOFFMANN LA ROCHE (CH) | 2013-02-27 | — | — | EP | disclosed |
| US-8022099-B2 | N-benzyl pyrrolidine derivatives | HOFFMANN-LA ROCHE INC. (US) | 2011-09-20 | — | — | US | disclosed |
| EP-2364295-A1 | 3-(BENZYLAMINO)-PYRROLIDINE DERIVATIVES AND THEIR USE AS NK-3 RECEPTOR ANTAGONISTS | F. Hoffmann-La Roche AG (CH) | 2011-09-14 | — | — | EP | disclosed |
| WO-2010060703-A1 | 3-(BENZYLAMINO)-PYRROLIDINE DERIVATIVES AND THEIR USE AS NK-3 RECEPTOR ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2010-06-03 | — | — | WO | disclosed |
| US-20100113424-A1 | N-BENZYL PYRROLIDINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2010-05-06 | — | — | US | disclosed |
| US-4840956-A | TREATING GRAM-POSITIVE BACTERIA | WARNER-LAMBERT COMPANY (US) | 1989-06-20 | — | — | US | disclosed |
| US-4735949-A | BROAD SPECTRA; GRAMPOSITIVE BACTERIA; BURN INJURIES | WARNER-LAMBERT COMPANY (US) | 1988-04-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100113424-A1 | N-BENZYL PYRROLIDINE DERIVATIVES | OPRK1, OPRD1, OPRL1 | CCR5 1534/4885RORC 730/4885HTR2C 58/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.